NONMEM Users Network Archive

Hosted by Cognigen

Register to Get a First Look at Phoenix 7.0

From: Heather Deamond <Heather.Deamond>
Date: Tue, 23 Aug 2016 12:16:44 +0000

In today's drug development climate, scientists are exploring more efficien=
t and productive ways to rapidly characterize the pharmacokinetics and phar=
macodynamics (PK/PD) of investigational drugs, and effectively communicate =
the findings from PK/PD analyses and models to keep drug programs on track.=
 Are you using the right tools to support this critical work?

Phoenix(r) is the industry's premier software workbench for managing, analy=
zing and reporting PK/PD and toxicokinetic (TK) data. It is used worldwide =
by 6,000 researchers, 1,500 biopharmaceutical companies, 200 academic insti=
tutions, and global regulatory agencies, including seven divisions of the U=

To learn how the new features and enhancements in Phoenix 7.0 will help you=
 work faster and more efficiently, sign up for this free webinar with Dr. N=
athan Teuscher, VP of Pharmacometrics Solutions at Certara.

This webinar will demonstrate how you can better leverage the power of Phoe=
nix by a taking a look inside many of the improvements including:

  * An all new graphics engine that generates high resolution out-of-the-=
box publication-quality plots and figures
  * How you can cut your NCA analysis time in half with the redesigned Wi=
nNonlin(r) engine
  * Reduce analysis time with first-in-class integrated grid and cloud su=
pport for execution of NLME(tm) jobs on remote/parallel compute platforms
  * Many other new features incorporated into the Phoenix workbench, e.g.=
 informative diagnostic messages, support for delay differential equations,=
 and others
Topic: A First Look at Phoenix 7.0, the World's Most Advanced PK/PD Softwar=
e Workbench
Date: September 14th
Time: 11:00am EDT
If you would like to register, click on the link below!
Kind Regards,
Heather Deamond NOTICE: The information contained in this electroni=
c mail message is intended only for the personal and confidential use =
of the designated recipient(s) named above. This message may be an attorney=
-client communication, may be protected by the work product doctrine, =
and may be subject to a protective order. As such, this message is privileg=
ed and confidential. If the reader of this message is not the intended=
 recipient or an agent responsible for delivering it to the intended r=
ecipient, you are hereby notified that you have received this message in er=
ror and that any review, dissemination, distribution, or copying of th=
is message is strictly prohibited. If you have received this communica=
tion in error, please notify us immediately by telephone and e-mail and des=
troy any and all copies of this message in your possession (whether ha=
rd copies or electronically stored copies). Thank you. buSp9xeMeKEbrUz=

Received on Tue Aug 23 2016 - 08:16:44 EDT

The NONMEM Users Network is maintained by ICON plc. Requests to subscribe to the network should be sent to:

Once subscribed, you may contribute to the discussion by emailing: